Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Br J Haematol. 2022 Feb;196(4):814-829. doi: 10.1111/bjh.17811. Epub 2021 Aug 31.
The term diffuse large B-cell lymphoma (DLBCL) includes a heterogeneous collection of biologically distinct tumours. This heterogeneity currently presents a barrier to the successful deployment of novel, biologically targeted therapies. Molecular profiling studies have recently proposed new molecular classification systems. These have the potential to resolve the biological heterogeneity of DLBCL into manageable subgroups of tumours that rely on shared oncogenic programmes. In many cases these biological programmes straddle the boundaries of our existing systems for classifying B-cell lymphomas. Here we review the findings from these major molecular profiling studies with a specific focus on those that propose new genetic subgroups of DLBCL. We highlight the areas of consensus and discordance between these studies and discuss the implications for current clinical practice and for clinical trials. Finally, we address the outstanding challenges and solutions to the introduction of genomic subtyping and precision medicine in DLBCL.
弥漫性大 B 细胞淋巴瘤（DLBCL）一词包含了一组生物学特征明显不同的肿瘤。这种异质性目前是新型生物靶向治疗成功应用的障碍。分子谱分析研究最近提出了新的分子分类系统。这些系统有可能将 DLBCL 的生物学异质性分解为可管理的肿瘤亚群，这些亚群依赖于共同的致癌程序。在许多情况下，这些生物学程序跨越了我们现有的 B 细胞淋巴瘤分类系统的界限。在这里，我们将重点介绍那些提出新的 DLBCL 遗传亚群的主要分子谱分析研究的结果，对这些研究进行综述。我们强调了这些研究之间的共识和分歧领域，并讨论了对当前临床实践和临床试验的影响。最后，我们探讨了在 DLBCL 中引入基因组亚型和精准医疗的尚未解决的挑战和解决方案。
